TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Double-Blind, Placebo-Controlled, Study to Investigate the Safety and Efficacy of Lithium in Combination With Riluzole in Volunteers With Amyotrophic Lateral Sclerosis (ALS)
Brief Summary: The purpose of this study is to compare the effectiveness of lithium combined with riluzole to riluzole combined with placebo in people with amyotrophic lateral sclerosis.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lithium Carbonate, Drug: Riluzole | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Riluzole, Drug: placebo | Intervention Type: DRUG; Name: Lithium Carbonate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Riluzole; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: Thalidomide (drug); Assigned to Arm(s): N/A
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Real rTMS of the brain | Arm Label: B; Type: SHAM_COMPARATOR; Interventions: Procedure: Sham rTMS of the brain | Intervention Type: PROCEDURE; Name: Real rTMS of the brain; Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: Sham rTMS of the brain; Assigned to Arm(s): B
D: Intervention Type: DRUG; Name: minocycline; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Superficial Thrombophlebitis and Venous Thromboembolism: A Large Prospective Epidemiological Study
Brief Summary: We performed a national cross-sectional and prospective large epidemiological cohort study in patients with ST. Office- and hospital-based vascular medicine French practitioners enrolled all consecutive patients with a symptomatic ST of the lower limbs at least 5 cm long documented by compression ultrasonography. Follow-up was three months. All events were adjudicated by a central committee.


Options:
A: Arm Label: Fondaparinux 2.5mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fondaparinux 2.5mg or placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Fondaparinux 2.5mg or placebo | Intervention Type: DRUG; Name: Fondaparinux 2.5mg or placebo; Assigned to Arm(s): Fondaparinux 2.5mg, Placebo
B: Arm Label: 1; Type: N/A; Interventions: Procedure: compression ultrasonography at 3 months | Arm Label: 2; Type: N/A; Interventions: N/A | Intervention Type: PROCEDURE; Name: compression ultrasonography at 3 months; Assigned to Arm(s): 1
C: Arm Label: dalteparin 5000 I.U./24 h s.c.; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dalteparin | Arm Label: dalteparin 15000 I.U./24 h s.c.; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dalteparin | Intervention Type: DRUG; Name: Dalteparin; Assigned to Arm(s): dalteparin 5000 I.U./24 h s.c. | Intervention Type: DRUG; Name: Dalteparin; Assigned to Arm(s): dalteparin 15000 I.U./24 h s.c.
D: Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban | Arm Label: Fondaparinux; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fondaparinux | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Fondaparinux; Assigned to Arm(s): Fondaparinux

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Safety and Pharmacodynamics of Two Doses of Dabigatran Etexilate in Patients Undergoing Cardiac Catheterization
Brief Summary: To assess whether two doses of dabigatran etexilate (110 mg twice daily (b.i.d) and 150 mg twice daily (b.i.d)) as compared to unfractionated heparin (UFH), both in addition to a standard dual antiplatelet regimen, provide sufficient anticoagulation in the setting of elective percutaneous coronary intervention (PCI).


Options:
A: Arm Label: Dabigatran 110 mg; Type: EXPERIMENTAL; Interventions: Drug: dabigatran 110 mg | Arm Label: Dabigatran 150 mg; Type: EXPERIMENTAL; Interventions: Drug: dabigatran 150 mg | Arm Label: Unfractionated Heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: unfractionated heparin | Intervention Type: DRUG; Name: dabigatran 110 mg; Assigned to Arm(s): Dabigatran 110 mg | Intervention Type: DRUG; Name: dabigatran 150 mg; Assigned to Arm(s): Dabigatran 150 mg | Intervention Type: DRUG; Name: unfractionated heparin; Assigned to Arm(s): Unfractionated Heparin
B: Intervention Type: DRUG; Name: clopidogrel (SR25990C); Assigned to Arm(s): N/A
C: Arm Label: Dabigatran dose 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 2 | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin | Arm Label: Dabigatran dose 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 1 | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Dabigatran dose 1; Assigned to Arm(s): Dabigatran dose 1 | Intervention Type: DRUG; Name: Dabigatran dose 2; Assigned to Arm(s): Dabigatran dose 2
D: Intervention Type: DRUG; Name: SR34006 (idraparinux sodium) Injection; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin K antagonist (warfarin or acenocoumarol) tablets; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Primary Care Based Randomized Trial to Reduce Cancer Screening Disparities
Brief Summary: The purpose of this project is to improve cancer screening rates within practices serving low-income minority patients


Options:
A: Arm Label: Educational intervention; Type: EXPERIMENTAL; Interventions: Other: Educational intervention | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Educational intervention; Assigned to Arm(s): Educational intervention
B: Intervention Type: BEHAVIORAL; Name: Multifaceted intervention (patient education, physician guidelines, reminders); Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Early Intervention | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Delayed intervention | Intervention Type: BEHAVIORAL; Name: Early Intervention; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Delayed intervention; Assigned to Arm(s): 2
D: Intervention Type: PROCEDURE; Name: CT Scan; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Primary Care Based Randomized Trial to Reduce Cancer Screening Disparities
Brief Summary: The purpose of this project is to improve cancer screening rates within practices serving low-income minority patients


Options:
A: Arm Label: Standard care; Type: OTHER; Interventions: Behavioral: Standard Care | Arm Label: Sustained Care; Type: EXPERIMENTAL; Interventions: Behavioral: Sustained Care | Intervention Type: BEHAVIORAL; Name: Sustained Care; Assigned to Arm(s): Sustained Care | Intervention Type: BEHAVIORAL; Name: Standard Care; Assigned to Arm(s): Standard care
B: Arm Label: ISTOP-ADE; Type: EXPERIMENTAL; Interventions: Other: ISTOP-ADE | Arm Label: Routine care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: ISTOP-ADE; Assigned to Arm(s): ISTOP-ADE
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Early Intervention | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Delayed intervention | Intervention Type: BEHAVIORAL; Name: Early Intervention; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Delayed intervention; Assigned to Arm(s): 2
D: Arm Label: Automated Phone-Based Refill Reminders; Type: EXPERIMENTAL; Interventions: Behavioral: Automated Phone-Based Refill Reminders | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Automated Phone-Based Refill Reminders; Assigned to Arm(s): Automated Phone-Based Refill Reminders

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Double-Blind, Randomized, Efficacy and Safety Study of the TAK 491 Plus Chlorthalidone Fixed-Dose Combination Compared With TAK-491 and Hydrochlorothiazide Coadministration Therapy in Subjects With Moderate to Severe Essential Hypertension
Brief Summary: The purpose of this study is to compare the antihypertensive effect of chlorthalidone vs hydrochlorothiazide when each is used with azilsartan medoxomil, once daily (QD), in participants with moderate to severe essential hypertension.


Options:
A: Arm Label: Telmisartan; Type: ACTIVE_COMPARATOR; Interventions: Drug: Telmisartan | Arm Label: Telmisartan/hydrochlorothiazide; Type: EXPERIMENTAL; Interventions: Drug: Telmisartan, Drug: Hydrochlorothiazide | Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): Telmisartan | Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): Telmisartan/hydrochlorothiazide | Intervention Type: DRUG; Name: Hydrochlorothiazide; Assigned to Arm(s): Telmisartan/hydrochlorothiazide
B: Arm Label: polypill; Type: EXPERIMENTAL; Interventions: Drug: polypill | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Usual cardiovascular medications | Intervention Type: DRUG; Name: polypill; Assigned to Arm(s): polypill | Intervention Type: DRUG; Name: Usual cardiovascular medications; Assigned to Arm(s): Usual Care
C: Arm Label: Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Azilsartan medoxomil and chlorthalidone | Arm Label: Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Azilsartan medoxomil and hydrochlorothiazide | Intervention Type: DRUG; Name: Azilsartan medoxomil and chlorthalidone; Assigned to Arm(s): Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Intervention Type: DRUG; Name: Azilsartan medoxomil and hydrochlorothiazide; Assigned to Arm(s): Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD
D: Arm Label: The Red Heart Pill 2b (Polypill) (A); Type: EXPERIMENTAL; Interventions: Drug: Red Heart Pill 2b (Polypill) | Arm Label: Standard Practice Group (B); Type: ACTIVE_COMPARATOR; Interventions: Other: Standard Practice | Intervention Type: DRUG; Name: Red Heart Pill 2b (Polypill); Assigned to Arm(s): The Red Heart Pill 2b (Polypill) (A) | Intervention Type: OTHER; Name: Standard Practice; Assigned to Arm(s): Standard Practice Group (B)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 811 in Subjects With Systemic Lupus Erythematosus With and Without Glomerulonephritis
Brief Summary: This is a 2-part, multi-center, randomized, double-blind, placebo-controlled, multiple dose escalation study, enrolling approximately 48 subjects. Part A of the study will enroll subjects with Systemic Lupus Erythematosus (SLE) without Glomerulonephritis (GN) into 3 cohorts. Part B of the study will enroll SLE subjects with GN into 3 cohorts. The purpose of the study is to evaluate the multiple dose of AMG 811 on safety. Tolerability and pharmacokinetics.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: AMG 811 | Arm Label: AMG811; Type: OTHER; Interventions: Drug: AMG 811 | Intervention Type: DRUG; Name: AMG 811; Assigned to Arm(s): AMG811, Placebo
B: Arm Label: Low dose Cyclophosphamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclophosphamide, Drug: Azathioprine, Drug: Methylprednisolone | Arm Label: High Dose Cyclophosphamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclophosphamide, Drug: Azathioprine, Drug: Methylprednisolone | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): High Dose Cyclophosphamide, Low dose Cyclophosphamide | Intervention Type: DRUG; Name: Azathioprine; Assigned to Arm(s): High Dose Cyclophosphamide, Low dose Cyclophosphamide | Intervention Type: DRUG; Name: Methylprednisolone; Assigned to Arm(s): High Dose Cyclophosphamide, Low dose Cyclophosphamide
C: Arm Label: FK506+MMF; Type: ACTIVE_COMPARATOR; Interventions: Drug: Multitherapy | Intervention Type: DRUG; Name: Multitherapy; Assigned to Arm(s): FK506+MMF
D: Intervention Type: DRUG; Name: Abetimus sodium (LJP 394); Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 1356 (5 mg Administered Orally Once Daily) Over 18 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control (HbA1c 7.0-10%) Despite Background Therapy With a Sulfonylurea Drug.
Brief Summary: Efficacy and safety of BI 1356 compared to placebo in patients with type 2 diabetes who have insufficient glycaemic control despite treatment with a sulfonylurea drug.


Options:
A: Arm Label: Sitagliptin 100 mg; Type: EXPERIMENTAL; Interventions: Drug: sitagliptin (MK0431) | Arm Label: Glipizide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Comparator: glipizide | Intervention Type: DRUG; Name: sitagliptin (MK0431); Assigned to Arm(s): Sitagliptin 100 mg | Intervention Type: DRUG; Name: Comparator: glipizide; Assigned to Arm(s): Glipizide
B: Arm Label: BI 1356; Type: ACTIVE_COMPARATOR; Interventions: Drug: BI 1356 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BI 1356; Assigned to Arm(s): BI 1356 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Glimepiride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glimepiride, Drug: Metformin | Arm Label: Canagliflozin 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin (JNJ-28431754), Drug: Metformin | Arm Label: Canagliflozin 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin (JNJ-28431754), Drug: Metformin | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Glimepiride | Intervention Type: DRUG; Name: Canagliflozin (JNJ-28431754); Assigned to Arm(s): Canagliflozin 100 mg, Canagliflozin 300 mg | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Canagliflozin 100 mg, Canagliflozin 300 mg, Glimepiride
D: Arm Label: Canagliflozin 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin 300 mg, Drug: Metformin, Drug: Sulphonylurea | Arm Label: Sitagliptin 100 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sitagliptin 100 mg, Drug: Metformin, Drug: Sulphonylurea | Intervention Type: DRUG; Name: Sitagliptin 100 mg; Assigned to Arm(s): Sitagliptin 100 mg | Intervention Type: DRUG; Name: Canagliflozin 300 mg; Assigned to Arm(s): Canagliflozin 300 mg | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Canagliflozin 300 mg, Sitagliptin 100 mg | Intervention Type: DRUG; Name: Sulphonylurea; Assigned to Arm(s): Canagliflozin 300 mg, Sitagliptin 100 mg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 1356 (5 mg Administered Orally Once Daily) Over 18 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control (HbA1c 7.0-10%) Despite Background Therapy With a Sulfonylurea Drug.
Brief Summary: Efficacy and safety of BI 1356 compared to placebo in patients with type 2 diabetes who have insufficient glycaemic control despite treatment with a sulfonylurea drug.


Options:
A: Arm Label: Lira 1.8 mg; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 1.8 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: Treatment A; Type: EXPERIMENTAL; Interventions: Drug: LX4211 | Arm Label: LX4211 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: LX4211 Placebo | Intervention Type: DRUG; Name: LX4211; Assigned to Arm(s): Treatment A | Intervention Type: DRUG; Name: LX4211 Placebo; Assigned to Arm(s): LX4211 Placebo
C: Intervention Type: BEHAVIORAL; Name: Insulin; Assigned to Arm(s): N/A
D: Arm Label: BI 1356; Type: ACTIVE_COMPARATOR; Interventions: Drug: BI 1356 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BI 1356; Assigned to Arm(s): BI 1356 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: NOPHO Treatment Protocol for Children (1.0 - 17.9 Years of Age) and Young Adults(18.0-45.0 Years) With Acute Lymphoblastic Leukemia. Intermittent Versus Continuous PEG-asparaginase for Asparagine Depletion
Brief Summary: The purpose of this study is to investigate if intramuscular PEG-asparaginase administered either at six or two week intervals from day 92 until 8 months from diagnosis for patients with non-HR ALL will result in equal probability of Event Free Survival


Options:
A: Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Imatinib Mesylate; Assigned to Arm(s): N/A
B: Arm Label: Apixaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban | Arm Label: Placebo drug; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo drug | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Placebo drug; Assigned to Arm(s): Placebo drug
C: Arm Label: High Risk for VTE recieving dalteparin; Type: EXPERIMENTAL; Interventions: Drug: dalteparin injection | Arm Label: High Risk for VTE No therapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Low Risk for VTE; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: dalteparin injection; Assigned to Arm(s): High Risk for VTE recieving dalteparin
D: Arm Label: PEG-asparaginase 6 weeks intervals; Type: EXPERIMENTAL; Interventions: Drug: PEG Asparaginase at six weeks interval | Arm Label: PEG-Asparaginase 2 weeks intervals; Type: ACTIVE_COMPARATOR; Interventions: Drug: PEG Asparaginase at two weeks interval | Intervention Type: DRUG; Name: PEG Asparaginase at six weeks interval; Assigned to Arm(s): PEG-asparaginase 6 weeks intervals | Intervention Type: DRUG; Name: PEG Asparaginase at two weeks interval; Assigned to Arm(s): PEG-Asparaginase 2 weeks intervals

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: 2- Inhaled Milrinone Prevents the Increase in Pulmonary Artery Pressure After CPB
Brief Summary: Pulmonary hypertension is an important morbidity factor in patients having to undergo cardiac surgery with cardiopulmonary bypass (ECC). Milrinone used in inhalation, shows evidence of being a pulmonary vasodilator able to possibly contribute to the reduction of pressure on the pulmonary artery.


Options:
A: Arm Label: L; Type: EXPERIMENTAL; Interventions: Drug: levosimendan | Arm Label: P; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: levosimendan; Assigned to Arm(s): L | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): P
B: Arm Label: Normal saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline | Arm Label: Milrinone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Milrinone | Intervention Type: DRUG; Name: Milrinone; Assigned to Arm(s): Milrinone | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): Normal saline
C: Arm Label: Levosimendan; Type: EXPERIMENTAL; Interventions: Drug: Levosimendan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Levosimendan; Assigned to Arm(s): Levosimendan | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: levosimendan; Type: EXPERIMENTAL; Interventions: Drug: levosimendan | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: levosimendan; Assigned to Arm(s): levosimendan | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Role of Information Technology in the Primary Prevention of Type 2 Diabetes
Brief Summary: Type 2 diabetes is a major and increasing problem in India and the UK. In clinical trials it can be prevented in people at high risk by lifestyle intervention. While these trials established the proof of principle, they involved a degree of input from healthcare professionals not feasible outside the trial situation. We hypothesize that diabetes prevention can be achieved at lower cost using personalised feedback via mobile phone, based on information on healthy diet and physical activity habits. We shall develop research protocols and computerized algorithms to test this hypothesis in India for application subsequently in the UK and elsewhere.


Options:
A: Intervention Type: BEHAVIORAL; Name: diet- and exercise intervention; Assigned to Arm(s): N/A
B: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control arm (usual care/standard care arm) | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Experimental | Intervention Type: BEHAVIORAL; Name: Experimental; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Control arm (usual care/standard care arm); Assigned to Arm(s): 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Intensive lifestyle counselling | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Intensive lifestyle counselling; Assigned to Arm(s): 1
D: Arm Label: Usual Care Only; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care Only | Arm Label: Vida Sana; Type: EXPERIMENTAL; Interventions: Behavioral: Vida Sana | Intervention Type: BEHAVIORAL; Name: Vida Sana; Assigned to Arm(s): Vida Sana | Intervention Type: OTHER; Name: Usual Care Only; Assigned to Arm(s): Usual Care Only

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Multicenter, Phase 2 Study to Compare the Efficacy of Panitumumab in Combination With mFOLFOX6 to the Efficacy of Bevacizumab in Combination With mFOLFOX6 in Patients With Previously Untreated, KRAS Wild-Type, Unresectable, Metastatic Colorectal Cancer
Brief Summary: The primary objective of this study is to estimate the treatment effect on progression-free survival (PFS) of panitumumab relative to bevacizumab in combination with mFOLFOX6 chemotherapy as first-line therapy in patients with tumors expressing wild-type KRAS, unresectable mCRC.


Options:
A: Arm Label: Panitumumab Plus mFOLFOX6; Type: EXPERIMENTAL; Interventions: Drug: Panitumumab, Drug: mFOLFOX6 | Arm Label: Bevacizumab Plus mFOLFOX6; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab, Drug: mFOLFOX6 | Intervention Type: DRUG; Name: Panitumumab; Assigned to Arm(s): Panitumumab Plus mFOLFOX6 | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Bevacizumab Plus mFOLFOX6 | Intervention Type: DRUG; Name: mFOLFOX6; Assigned to Arm(s): Bevacizumab Plus mFOLFOX6, Panitumumab Plus mFOLFOX6
B: Arm Label: Panitumumab Plus FOLFIRI; Type: EXPERIMENTAL; Interventions: Drug: Panitumumab, Drug: FOLFIRI | Arm Label: FOLFIRI Alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: FOLFIRI | Intervention Type: DRUG; Name: Panitumumab; Assigned to Arm(s): Panitumumab Plus FOLFIRI | Intervention Type: DRUG; Name: FOLFIRI; Assigned to Arm(s): FOLFIRI Alone, Panitumumab Plus FOLFIRI
C: Intervention Type: BIOLOGICAL; Name: cetuximab; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: erlotinib (Tarceva), Drug: bevacizumab (Avastin) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab (Avastin) | Intervention Type: DRUG; Name: erlotinib (Tarceva); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: bevacizumab (Avastin); Assigned to Arm(s): 1, 2

Answer: A